drugset / Trial / NCT00743288

Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma

NCT00743288

Phase 1/2 Completed 40 enrolled Oncotherapeutics Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving melphalan together with panobinostat may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of melphalan when given together with panobinostat in treating patients with recurrent multiple myeloma.

Timeline

Start
2008-07
Primary completion
2012-11
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Melphalan Small molecule 0.05 mg/kg Oral
Subject Melphalan Small molecule 0.1 mg/kg Oral
Subject Panobinostat Small molecule 10 mg Oral
Subject Panobinostat Small molecule 15 mg Oral
Subject Panobinostat Small molecule 20 mg Oral

Indications